Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Radicava (edaravone) is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).
• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• ALSFRS-R Scores: Edaravone demonstrated a slightly slower reduction in ALSFRS-R score at 6 months compared to placebo (MD 1.01, 95% CI -0.87 to 3.09, p = 0.293), but observational studies showed no benefit (MD 1.85, 95% CI -2.05 to 5.75, p = 0.352). Significant differences were noted in other studies at 24 weeks (MD 1.63, 95% CI 0.26-3.00, p = 0.02) and between groups (MD 1.33, 95% CI 0.33-2.34, p = 0.009).
• Survival Rates: Edaravone improved survival rates at 18, 24, and 30 months with risk ratios of 1.03 (95% CI 1.02 to 1.24, p = 0.02), 1.22 (95% CI 1.06 to 1.41, p = 0.007), and 1.17 (95% CI 1.01 to 1.34, p = 0.03), respectively.
• Other Functional Outcomes: Increased grip strength (MD 0.26, 95% CI 0.03-0.49, p = 0.03) and modified Norris Scale scores (MD 2.81, 95% CI 1.18-4.43, p = 0.0007) were reported for edaravone, with no significant differences in FVC%, pinch strength, or ALSAQ-40 scores. Another study reported no effect on functional outcomes.
• There were no significant differences in the incidence of adverse events, serious adverse events, or deaths between the edaravone and placebo groups across multiple studies (e.g., RR for AEs 0.09, 95% CI 0.93-1.05, p = 0.65; RR for SAEs 0.72, 95% CI 0.52-1.00, p = 0.05; OR for AEs 1.22, 95% CI 0.68-2.19, p = 0.50; OR for SAEs 0.71, 95% CI 0.43-1.19, p = 0.20).
• No significant safety concerns or adverse effects were highlighted in the studies.
• There is no population types or subgroups information available in the reviewed studies.